Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules

Lung cancer is the leading cause of cancer-related mortality worldwide, making early diagnosis and intervention critical. With the widespread adoption of low-dose computed tomography (LDCT) screening, the detection rate of pulmonary ground-glass nodules (GGNs) has increased significantly. Although video-assisted thoracoscopic surgery (VATS) remains the standard treatment for early-stage lung cancer, a considerable proportion of patients are ineligible for surgery due to advanced age, impaired cardiopulmonary function, or multiple nodules. Cryoablation, a minimally invasive ablation technique,

Trial Details

NCT ID
NCT07232433
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cryoablation
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Malignancy confirmed by histopathology or multidisciplinary team (MDT) discussion.
  • For a solitary GGN: size between 6-30 mm. For multiple GGNs: each measuring 6-30 mm, with no more than 3 nodules deemed to require treatment upon M…
  • Patient is ineligible for or unwilling to undergo video-assisted thoracoscopic surgery (VATS).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →